Trending Topic

2 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

From advances in targeted therapies to the integration of AI and steps towards precision medicine, 2024 brought many exciting developments in the field. With 2025 now unfolding, many of these are likely to continue gaining momentum and potentially redefine patient care. In this latest edition of touchREVIEWS in RMD, we’re excited to present a collection […]

Robert Terkeltaub, ACR 2021: Tigulixostat for the Treatment of Gout with Hyperuricemia

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Published Online: Nov 23rd 2021

It was a pleasure to meet with Professor Robert Terkeltaub (UC San Diego, San Diego, California, USA) to discuss the efficacy and safety findings from the phase 2 study of tigulixostat in gout with hyperuricemia (NCT03934099).

This information is brought to you by Touch Medical Media and is not sponsored by, nor a part of, the American College of Rheumatology.

The abstract ‘Phase 2 Study Results from a Randomized, Double-blind, Placebo-controlled, Dose-finding Study to Evaluate Efficacy and Safety of Tigulixostat, a Novel Non-purine Selective Xanthine Oxidase Inhibitor, in Gout Patients with Hyperuricemia.‘ (Abstract number: L05) was presented at the ACR Convergence, 5-9 November 2021.

Questions

  1. What are the limitations of current treatment options for gout? (0:12)
  2. Could you tell us a little about tigulixostat and its potential advantages over febuxostat? (1:00)
  3. What were the aims and methodology of your Phase II study investigating tigulixostat? (2:16)
  4. What were the efficacy and safety findings with the different dose levels? (3:51)
  5. What will be the next step in the clinical development of tigulixostat? (5:39)

Disclosures: Robert Terkeltaub discloses research grants from Astra-Zeneca and consulting for LG, Allena, Dyve, Fortress Bio, Astra-Zeneca.

Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones.

Filmed in coverage of the virtual ACR Convergence 2021.

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Close Popup